News
FDA approves new antibiotic to treat community-acquired bacterial pneumonia
The U.S. Food and Drug Administration today approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia.
GNA NOW kicks off its battle against antimicrobial resistance
On July 1st, a new partnership launched in the fight against antimicrobial resistance. GNA NOW (Gram-Negative Antibacterials NOW) will work on the development of novel antibacterial agents against antimicrobial resistance in gram-negative bacteria. The project is a multi-stakeholder effort, led by Evotec and managed by Lygature, with other partners from academia, industry and SMEs: Nosopharm, BIOASTER, Helmholtz Centre for Infection Research, North Bristol National Health Service Trust, University of Liverpool, Inserm, Erasmus Medical Center, Medical University of Vienna, and Fraunhofer IME.
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis
Pretomanid, developed by the non-profit TB Alliance, has received U.S. approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.
EU awards EUR 18 million for research into new antibiotics
An international consortium of research groups aims to develop novel antibiotics against the tuberculosis bacteria and two other deadly bacteria. The European Union has awarded a total of EUR 18 million to the RespiriTB and RespiriNTM projects. Researchers from the Leiden University Medical Centre (LUMC) will be taking part in the study, that is set to last six years.
AGILeBiotics receives NADP lead development voucher for further development of antibiotics
AGILeBiotics has been awarded a Lead Development Voucher by the Netherlands Antibiotic Development Platform (NADP). The total amount of €50.000 will be allocated to the pre-clinical R&D activities. With this financial support the company will test its antibiotic candidates in a clinically relevant animal model of infection. The next goal is the nomination of an antibiotic candidate for pre-clinical development.
ZonMw survey on resources related to antimicrobial resistance research
ZonMw (the Netherlands Organisation for Health Research and Development) is performing, on behalf of JPIAMR and the recently started consortium VALUE-Dx, a survey on resources (collections of biological material and databases) that are relevant for antimicrobial resistance (AMR) research. In parallel, they collect information about services that are provided by research infrastructures and some biobanks.